Scinai Immunotherapeutics Ltd. (SCNI) Form 6-K — Nov 9, 2026
Scinai Immunotherapeutics (NASDAQ: SCNI) reported nine-month 2026 revenue of $2.8 million, up 167% from $1.05 million a year earlier, driven by its CDMO business including the Yavne operations acquired from Recipharm Israel in February 2026. Committed Customer Orders reached approximately $8.32 million as of November 4, 2026, up more than 330% from $1.9 million at year-end 2025, anchored by an expanded U.S. customer agreement with roughly $5.1 million in committed base services. October financings added about $5.3 million in net proceeds, lifting bank balances to approximately $8.1 million and extending the operating runway to late 2027.
Key figures
- Revenue
- 2805000
- Revenue Yoy
- 167%
- Total Assets
- 15698000
- Cash Position
- $1.70 million cash and equivalents plus $195K restricted cash at Sep 30, 2026; ~$8.1 million bank balances as of October 27, 2026
- Shares Outstanding
- 54129107584
- Runway
- to late 2027, potentially Q3 2028 with uncommitted work
- Gross loss
- $2.97 million (vs $1.91 million prior year)
- Operating loss
- $6.56 million (vs $5.64 million prior year)
- Share count growth
- from 13.87 billion to 54.13 billion shares during 2026
- Operating cash burn
- $5.80 million used in operations
- Bargain purchase gain
- $6.40 million noncash
- Committed customer orders
- $8.32 million (up from $1.9 million at year-end 2025, +330%)
- October financing net proceeds
- $5.3 million
- Us customer committed base fees
- $5.1 million
- Potential additional clinical manufacturing value
- $5.85 million (uncommitted)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.